I am responding to the article by Dr. Stephen Stahl entitled "Antipsychotic treatment of psychotic major depression: potential role of the a receptor" (CNS Spear. 2005;10(4):319-323). 1 The following case report seems to illustrate the role of fluvoxamine as an antipsychotic, thus supporting Dr. Stahl's hypothesis.
BACKGROUND
Fluvoxamine has traditionally been considered an antidepressant which works well both to treat obsessive-compulsive disorder and for depressive disorders. However, there has been some recent speculation about using it as an antipsychotic, either as monotherapy or as an augmenting agent. A brief report by Levkovitz and colleagues 2 discussed a small study in which low-dose fluvoxemine was used to augment perphenazine in psychotic Alzheimer's patients, with good antipsychotic effect. More recently, Stahl 1 proposed that the selective serotonin reuptake inhibitor (SSRI) a receptor may be responsible for previously unknown antipsychotic effects and he cited several studies involving SSRI monotherapy efficacy for major depression with psychosis. The following case seems to support the evidence that fluvoxamine in particular may exert an effect on psychosis.
CASE PRESENTATION
A 53-year-old African American female with a history of schizoaffective disorder was taking risperidone and fluvoxamine for 5 years with good effect, but had some chronic baseline auditory hallucinations. The decision was made to start her on risperidone long-acting injection in February 2004, and over the course of the next 6 months, her dose of risperidone long-acting injection was titrated up to 50 mg every 2 weeks and oral risperidone was discontinued. Her auditory hallucinations stopped and the patient remained symptom free. In December 2004, she self-discontinued fluvoxamine due to possible cognitive side effects. In January 2005, escitalopram was begun for increasing depressive symptoms. No dosage change was made in her risperidone long-acting injection. Her depression improved but she began experiencing auditory hallucinations again in March.
Despite the addition of oral risperidone, the patient continued to experience hallucinations until fluvoxamine was restarted in late March, at which point her psychosis began to improve. However, she self-discontinued the fluvoxamine in mid-April, after which she began experiencing auditory hallucinations and delusions once more, decompensating until she required psychiatric hospitalization at the end of the month. Fluvoxamine was restarted with no other medication additions or changes, and currently her hallucinations are much decreased and continuing to improve.
CONCLUSION
Although this patient did not do well while taking escitalopram, she began to recover once fluvoxamine was restarted. Since there were no other medication changes that could account for her reduction in symptoms, it is likely that fluvoxamine has had a role in the past in maintaining her stability and has acted more recently to reduce her positive symptoms of schizophrenia. This case seems to support the interesting new hypothesis that fluvoxamine may be useful in controlling psychotic symptoms. 
